Emergent BioSolutions Reports Third Quarter and Nine Months 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Emergent BioSolutions (EBS) Tops Q3 EPS by 28c
November 5, 2015 4:58 PM ESTEmergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.83, $0.28 better than the analyst estimate of $0.55. Revenue for the quarter came in at $164.9 million versus the consensus estimate of $151.42 million.
Emergent BioSolutions sees FY2015 revenue of $510-540 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
... More